(
ITN090ST
|
ATTAIN
)
Principal Investigator:
Flavio Vincenti | University of California San Francisco | San Francisco, CA
Rajalingam Raja | University of California San Francisco | San Francisco, CA
The goal of ATTAIN is to study whether using two drugs, daratumumab and belatacept, together can lower the number of plasma cells in “highly sensitized” people on the kidney transplant waiting list.
Category:
Transplantation
|
Specific Category:
Kidney Transplantation
|
Status:
Enrollment
Learn more:
(
ITN089ST
|
ADAPT
)
Principal Investigator:
Stuart Knechtle | Duke University School of Medicine | Durham, NC
The goal of the ADAPT study is to study whether using two drugs, carfilzomib and belatacept, together can lower the number of plasma cells in “highly sensitized” people on the kidney transplant waiting list.
Category:
Transplantation
|
Specific Category:
Kidney Transplantation
|
Status:
Enrollment
Learn more:
